Novo Nordisk A/S (NYSE: NVO) announced positive topline results from the Phase III REIMAGINE 5 and REDEFINE 9 clinical trials of once‑weekly CagriSema (cagrilintide and semaglutide), its investigational innovator combination therapy for weight management, showing superiority over tirzepatide on weight loss in a direct head‑to‑head comparison and a 21.0% weight reduction versus placebo in a separate pivotal study.
Trial Snapshot
| Item | Detail |
|---|---|
| Sponsor | Novo Nordisk A/S (NYSE: NVO) |
| Product | CagriSema (cagrilintide + semaglutide), once‑weekly subcutaneous injectable |
| Status | Investigational innovator drug |
| Trials | REIMAGINE 5 (head‑to‑head vs tirzepatide) and REDEFINE 9 (placebo‑controlled) |
| Phase | Phase III |
| Announcement | Topline results, 21 Sep 2026 |
| Key Outcome | CagriSema superior to tirzepatide for weight loss; non‑inferior on HbA1c; 21.0% vs 2.0% reduction vs placebo in REDEFINE 9 |
Drug Profile & Mechanism of Action
- Molecule: CagriSema is a fixed‑ratio combination of cagrilintide, a long‑acting amylin receptor agonist, and semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist, formulated for once‑weekly subcutaneous administration.
- Dual‑Pathway Rationale: By simultaneously engaging the amylin and GLP‑1 pathways, CagriSema is designed to enhance satiety and reduce energy intake through complementary mechanisms, potentially delivering greater weight loss than either single‑agent incretin therapy.
- Clinical Positioning: The combination is being developed by Novo Nordisk as a next‑generation obesity treatment candidate, extending the franchise built on semaglutide (Wegovy/Ozempic).
- Comparator Context: REIMAGINE 5 benchmarked CagriSema (1.0 mg/1.0 mg) directly against tirzepatide (5 mg), the dual GIP/GLP‑1 receptor agonist marketed by Eli Lilly, a first‑class head‑to‑head readout between the two leading obesity franchises.
Clinical Evidence – Phase III REIMAGINE 5 (vs Tirzepatide)
| Endpoint | CagriSema 1.0 mg/1.0 mg | Tirzepatide 5 mg | Outcome |
|---|---|---|---|
| Estimated Average Weight Loss | 12.4% | 9.1% | Superiority achieved |
| HbA1c Reduction | 1.71% | 1.67% | Non‑inferiority confirmed |
REIMAGINE 5 established that once‑weekly CagriSema (1.0 mg/1.0 mg) was superior to tirzepatide (5 mg) for weight loss while confirming non‑inferiority in glycemic control, a dual win in the first direct Phase III comparison between the two leading obesity assets.
Clinical Evidence – Phase III REDEFINE 9 (vs Placebo)
| Endpoint | CagriSema 1.0 mg/1.0 mg | Placebo | Outcome |
|---|---|---|---|
| Weight Reduction | 21.0% | 2.0% | Primary superiority endpoint met |
| Systolic Blood Pressure | Greater improvement vs placebo | – | Prespecified supportive endpoint met |
| Waist‑to‑Height Ratio | Greater improvement vs placebo | – | Prespecified supportive endpoint met |
| Fasting Lipid Profile | Greater improvement vs placebo | – | Prespecified supportive endpoint met |
In REDEFINE 9, CagriSema delivered a 21.0% weight reduction versus 2.0% for placebo, meeting its primary superiority endpoint and demonstrating broader cardiometabolic benefits across prespecified supportive endpoints — detailed subgroup and safety data not yet disclosed.
Market Impact & Outlook
- Head‑to‑Head Advantage: The REIMAGINE 5 result gives Novo Nordisk a differentiated efficacy claim directly against tirzepatide at the compared doses, a potent marketing and payer‑negotiation asset in the fiercely competitive obesity market.
- Metabolic Profile Strength: Non‑inferior HbA1c reduction alongside superior weight loss positions CagriSema as a single therapy addressing both adiposity and glycemic control.
- Cardiometabolic Differentiation: Improvements in systolic blood pressure, waist‑to‑height ratio, and fasting lipids in REDEFINE 9 support a broader metabolic risk‑reduction narrative beyond scale weight.
- Regulatory Path: With two Phase III trials meeting their endpoints, Novo Nordisk is expected to advance CagriSema’s registrational program; submission timing and target indications were not disclosed in the topline announcement.
- Competitive Dynamics: The readout intensifies the incretin franchise rivalry, with once‑weekly dosing of a dual‑mechanism combination potentially setting a new efficacy benchmark in obesity pharmacotherapy.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory submissions and outcomes, and commercial expectations for CagriSema. Actual results may differ materially due to risks including final data analyses, regulatory determinations, competitive dynamics, and market adoption.-Fineline Info & Tech
